Profile data is unavailable for this security.
About the company
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. The Company’s product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFb1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. The Company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFb1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFb1 presented by cells of the immune system.
- Revenue in USD (TTM)0.00
- Net income in USD-183.26m
- Incorporated2017
- Employees150.00
- LocationScholar Rock Holding Corp301 BINNEY STREET, 3RD FLOORCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 259-3860
- Fax+1 (302) 655-5049
- Websitehttps://scholarrock.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cassava Sciences Inc | 0.00 | -47.90m | 1.03bn | 29.00 | -- | 11.86 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.06bn | 267.00 | -- | -- | -- | 2.55 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 1.06bn | 296.00 | -- | 4.68 | -- | 9.92 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Silence Therapeutics plc | 32.14m | -54.80m | 1.07bn | 116.00 | -- | 38.52 | -- | 33.19 | -0.4909 | -0.4909 | 0.2888 | 0.1817 | 0.2521 | -- | 44.40 | -- | -42.98 | -43.60 | -53.46 | -54.91 | 59.34 | -- | -170.51 | -287.30 | -- | -70.26 | 0.0157 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.10bn | 197.00 | 16.35 | 4.96 | 4.59 | 1.94 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 1.11bn | 586.00 | -- | 0.9823 | -- | 31.06 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Enliven Therapeutics Inc | 0.00 | -71.58m | 1.12bn | 46.00 | -- | 4.00 | -- | -- | -2.18 | -2.18 | 0.00 | 5.95 | 0.00 | -- | -- | 0.00 | -40.31 | -42.26 | -44.80 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -183.26m | 1.14bn | 150.00 | -- | 6.25 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 1.17bn | 278.00 | -- | 4.96 | -- | 5.21 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Pharvaris NV | 0.00 | -109.60m | 1.17bn | 82.00 | -- | 2.72 | -- | -- | -2.74 | -2.74 | 0.00 | 7.98 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
| MannKind Corp | 224.60m | 8.49m | 1.25bn | 414.00 | 195.90 | -- | 92.93 | 5.57 | 0.0234 | 0.0234 | 0.7589 | -0.8492 | 0.5766 | 2.69 | 11.34 | 542,509.70 | 2.18 | -26.07 | 2.84 | -37.80 | 70.99 | 59.68 | 3.78 | -57.61 | 3.57 | 1.50 | 1.80 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Prothena Corporation PLC | 89.25m | -172.40m | 1.26bn | 173.00 | -- | 2.50 | -- | 14.09 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Data as of May 16 2024. Currency figures normalised to Scholar Rock Holding Corp's reporting currency: US Dollar USD
66.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 11.26m | 14.46% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 10.41m | 13.37% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 8.09m | 10.39% |
| Redmile Group LLCas of 31 Dec 2023 | 6.40m | 8.22% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.29m | 5.51% |
| Polar Capital LLPas of 31 Dec 2023 | 2.94m | 3.78% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.89m | 3.72% |
| Bellevue Asset Management AGas of 31 Dec 2023 | 2.17m | 2.79% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.16m | 2.77% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 1.34m | 1.72% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
